ChromaDex Corp (CDXC)

4.55
0.14 3.00
NASDAQ : Health Care
Prev Close 4.69
Open 4.77
Day Low/High 4.62 / 4.77
52 Wk Low/High 2.46 / 6.18
Volume 24.04K
Avg Volume 306.90K
Exchange NASDAQ
Shares Outstanding 48.06M
Market Cap 226.36M
EPS -0.10
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

ChromaDex® To Report Second Quarter 2017 Financial Results On Thursday, August 10, 2017

ChromaDex® To Report Second Quarter 2017 Financial Results On Thursday, August 10, 2017

Company Will Host Investor Conference Call on Thursday, August 10, 2017

ChromaDex Sponsors Global Gathering Of Scientific Leaders In NAD+ Metabolism And Signaling At The 2017 Federation Of American Societies For Experimental Biology Conference

ChromaDex Sponsors Global Gathering Of Scientific Leaders In NAD+ Metabolism And Signaling At The 2017 Federation Of American Societies For Experimental Biology Conference

Findings from the University of Colorado Boulder Nicotinamide Riboside Human Clinical Trial, to be Presented to the Scientific Community

Short Interest Makes 19.6% Move For CDXC

The most recent short interest data has been released for the 06/15/2017 settlement date, which shows a 541,781 share increase in total short interest for ChromaDex Corp , to 3,305,741, an increase of 19.60% since 05/31/2017. Total short interest is just one way to look at short data; another metric that we here at Dividend Channel find particularly useful is the "days to cover" metric because it considers both the total shares short and the average daily volume of shares traded.

ChromaDex Appoints Harvard Medical School Professor Of Neurology, Dr. Rudolph Tanzi, To The Scientific Advisory Board

Global Alzheimer's Thought Leader to Assist in Exploring Potential for Nicotinamide Riboside in Brain and Neuronal Health

Short Interest Moves 12.5% Higher For CDXC

The most recent short interest data has been released for the 05/31/2017 settlement date, which shows a 307,817 share increase in total short interest for ChromaDex Corp , to 2,763,960, an increase of 12.53% since 05/15/2017. Total short interest is just one way to look at short data; another metric that we here at Dividend Channel find particularly useful is the "days to cover" metric because it considers both the total shares short and the average daily volume of shares traded.

ChromaDex Names World's Leading Expert On Nicotinamide Riboside And NAD As Chief Scientific Advisor

Charles Brenner, PhD, an investigator on the forefront of metabolism research, to champion the advancement of NR and NAD boosting technologies

NIAGEN® Nicotinamide Riboside Launches Into The Functional Food Space

Barology's Live Younger™ bar offers consumers a new way to help boost cellular metabolism and cellular energy production

ChromaDex Reports First Quarter 2017 Financial Results

Changes in Q1 and new investor set the foundation for success with NIAGEN®

ChromaDex To Report First Quarter 2017 Financial Results On Thursday, May 11, 2017

Company Will Host Investor Conference Call on Thursday, May 11, 2017

ChromaDex Reports 2016 Record Revenue As Ingredient Sales Grew 34%

Q4 Total Revenue Increased 29% and 2016 Total Revenue Increased 22%

ChromaDex To Report Year End 2016 Financial Results On Thursday, March 16, 2017

Company Will Host Investor Conference Call on Friday, March 17, 2017

Study Published In PAIN Reveals Nicotinamide Riboside Is An Effective Tool In Relieving Chemotherapy-Induced Peripheral Neuropathy Induced By A Common Anticancer Agent

Early findings demonstrated in female rats may one day lead to reductions in the neuropathic pain experienced by millions of breast and ovarian cancer patients and survivors

ChromaDex Expects To Report Record Fourth Quarter As Revenue Increased Approximately 29%

Q4 2016 Revenue is Expected to be Approximately $5.6 Million with Full-Year 2016 Revenue of Approximately $26.8 million

ChromaDex Opens New State-of-the-Art Research And Development Center In Longmont

ChromaDex Opens New State-of-the-Art Research And Development Center In Longmont

R&D Facility an Important Milestone for ChromaDex to Continue Global Leadership in the Identification and Development of NAD+ Metabolites

TheStreet Quant Rating: D (Sell)